Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SC262 |
| Synonyms | |
| Therapy Description |
SC262 comprises allogeneic CD4+ and CD8+ T-lymphocytes engineered to express CD47 and a chimeric antigen receptor (CAR) targeting CD22, and with disruption of MHC class I and class II molecule expression, which potentially induce cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing CD22 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SC262 | SC-262|SC 262 | CD22 Immune Cell Therapy 13 | SC262 comprises allogeneic CD4+ and CD8+ T-lymphocytes engineered to express CD47 and a chimeric antigen receptor (CAR) targeting CD22, and with disruption of MHC class I and class II molecule expression, which potentially induce cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing CD22 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06285422 | Phase I | Cyclophosphamide + Fludarabine SC262 | Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | Active, not recruiting | USA | 0 |